Teva’s 'Key Ingredient' For Growth: Biosimilars
Teva has conducted due diligence on 36 biosimilar companies with the aim of signing a partner soon to fill a critical gap in its generics pipeline.
You may also be interested in...
Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.
Radius Health's pricing and reimbursement strategy has been successful, at least with Express Scripts, which included its bone-builder Tymlos on a 2018 formulary that excludes several brand-name drugs.
Dealmaking is advancing the biosimilar field. Since 2000, the volume of biosimilar deals has grown at a 15% compound annual rate.